Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response

Pharmacogenomics

Volumn 12, Issue 4, 2011, Pages 471-480

  Ramsey, Timothy L ^a   Meltzer, Herbert Y ^b   Brock, Guy N ^c   Mehrotra, Bharat ^a   Jayathilake, Karu ^b   Bobo, William V ^b   Brennan, Mark D ^a  

^a SureGene LLC   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

CATIE; olanzapine; pharmacogenomics; risperidone

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; GENE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SULT4A1 GENE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG RESISTANCE; FEMALE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; SULFOTRANSFERASES;

EID: 79955530748     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.205     Document Type: Article

References (24)

1. Liyou NE, Buller KM, Tresillian MJ et al.: Localization of a brain sulfotransferase, SULT4A1, in the human and rat brain: an immunohistochemical study. J. Histochem. Cytochem. 51(12), 1655-1664 (2003)., This study demonstrates that sulfotransferase-4A1 (SULT4A1) is a brain-specific enzyme. (Pubitemid 37475438)
2. Allali-Hassani A, Pan PW, Dombrovski L et al.: Structural and chemical profiling of the human cytosolic sulfotransferases. PLoS Biol. 5(5), e97 (2007).
3. Minchin RF, Lewis A, Mitchell D, Kadlubar FF, McManus ME: Sulfotransferase 4A1. Int. J. Biochem. Cell Biol. 40(12), 2686-2691 (2008).
4. Brennan MD, Condra J: Transmission disequilibrium suggests a role for the sulfotransferase-4A1 gene in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139(1), 69-72 (2005).,., First discovery of SULT4A1 as a candidate gene for schizophrenia. (Pubitemid 41552301)
5. Meltzer HY, Brennan MD, Woodward ND, Jayathilake K: Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophr. Res. 106(2-3), 258-264 (2008).,., First indication that SULT4A1 impacts clinical presentation.
6. Lieberman JA, Stroup TS, McEvoy JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005)., Description of primary outcomes in Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. (Pubitemid 41345943)
7. Stroup TS, McEvoy JP, Swartz MS et al.: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 29(1), 15-31 (2003). (Pubitemid 36871054)
8. Sullivan PF, Lin D, Tzeng JY et al.: Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol. Psychiatry 13(6), 570-584 (2008). (Pubitemid 351704941)
9. Crowley JJ, Keefe RS, Perkins DO, Stroup TS, Lieberman JA, Sullivan PF: The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B(7), 1298-1300 (2008) .
10. van den Oord EJ, Adkins DE, McClay J, Lieberman J, Sullivan PF: A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. Schizophr. Res. 107(1), 13-21 (2009).
11. McClay JL, Adkins DE, Aberg K et al.: Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol. Psychiatry 16(1), 76-85 (2011).
12. Campbell DB, Lange LA, Skelly T, Lieberman J, Levitt P, Sullivan PF: Association of RGS2 and RGS5 variants with schizophrenia symptom severity. Schizophr. Res. 101(1-3), 67-75 (2008).
13. Need AC, Keefe RS, Ge D et al.: Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur. J. Hum. Genet. 17(7), 946-957 (2009)., Demonstrated the peformance of other candidate genes for antipsychotic response.
14. Meltzer HY: Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences? Int. J. Neuropsychopharmacol. 8(2), 153-156 (2005). (Pubitemid 40769255)
15. Condra JA, Neibergs H, Wei W, Brennan MD: Evidence for two schizophrenia susceptibility genes on chromosome 22q13. Psychiatr. Genet. 17(5), 292-298 (2007). (Pubitemid 47345751)
16. Need AC, Ge D, Weale ME et al.: A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet. 5(2), e1000373 (2009).
17. Purcell S, Neale B, Todd-Brown K et al.: PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007). (Pubitemid 47330214)
18. Everitt B, Rabe-Hesketh S: Analyzing Medical Data Using S-?PLUS. Springer-Verlag, NY, USA, 251-260 (2001).
19. Pinheiro JC, Bates DM: Mixed Effects Models in S and S-?PLUS. Springer-Verlag, NY, USA, 133-197 (2000).
20. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2), 263-265 (2005). (Pubitemid 40202029)
21. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373(9657), 31-41 (2009).
22. Fijal BA, Kinon BJ, Kapur S et al.: Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J. 9(5), 311-318 (2009).
23. Ikeda M, Tomita Y, Mouri A et al.: Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol. Psychiatry 67(3), 263-269 (2010).
24. Kantrowitz JT, Citrome L: Olanzapine: review of safety 2008. Expert Opin. Drug Saf. 7(6), 761-769 (2008).